이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

절제 불가능 또는 전이성 흑색종에 대한 ST-1898 연구

2026년 11월 3일 업데이트: Beijing Scitech-Mq Pharmaceuticals Limited

절제 불가능하거나 전이성 흑색종 환자를 대상으로 ST-1898의 효능과 안전성을 평가하기 위한 Ib/II상 연구

ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in subjects with unresectable or metastatic melanoma.

In phase Ib, the primary objectives are to assess the safety and tolerability, and to determine Recommended Phase 2 dose (RP2D) of ST-1898 tablets in subjects with unresectable or metastatic melanoma. Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy.

In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metastatic melanoma. The secondary objective is to evaluate the safety of ST-1898 tablets.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

64

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Beijing, 중국, 100142
        • Peking University Cancer Hospital & Institute

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Age >= 18 years

  2. Life expectancy of three months or more

  3. Histologically or cytologically confirmed unresectable or metastatic stage III or IV acral melanoma that was progressed with conventional therapy

  4. Recommendation of subject offering archived tissue sample or previous biomarker test report. If archived tumor sample is not available, a fresh biopsy is optional, which need to be taken from needle biopsy or core needle biopsy (fine needle biopsy not allowed)

  5. Eastern Cooperative Oncology Group performance status (PS) ≤ 1

  6. At least one measurable lesion per RECIST 1.1

  7. Has adequate organ function defined as follows:

    • Absolute neutrophil count ≥ 1.5 ×10^9/L, Platelets ≥ 75× 10^9/L and Hemoglobin ≥ 90 g/L (no blood transfusions, no platelet transfusions and no use of colony stimulating factor within 2 weeks prior to routine blood test) at screening;
    • Serum creatinine ≤1.5 × upper limit of normal (ULN)
    • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 ULN, AST/ALT ≤ 5 ULN for liver metastasis;
    • Total bilirubin ≤ 1.5 ULN
    • International normalized ratio (INR) ≤ 1.5 ULN, or prothrombin time (PT) ≤1.5 ULN
    • Activated partial thromboplastin time (APTT) ≤1.5 ULN
    • Serum albumin ≥30 g/L
  8. Willing and able to provide written Informed consent.

  9. Eligible male and female subjects with fertility activity or their sexual partners must use effective contraception during study period and though 90 days after last study treatment. Women of child-bearing age must have a negative serum pregnancy test within 7 days before first study treatment

Exclusion Criteria

  1. Subjects with one of the following conditions prior to first dose, including, but not limiting to:

    • A history of antitumor therapy within 4 weeks, including chemotherapy, radiotherapy, biotherapy, endocrine therapy or immunotherapy, etc.;
    • A history of oral fluoropyrimidines and small molecular targeted-drug therapy within 2 weeks or 5 half-life time (the longer time taken as final);
    • A history of traditional Chinese medicine with antitumor indication within 2 weeks;
  2. A history of being participant in clinical trial of other unapproved drugs within 4 weeks;

  3. A major operation or severe trauma within 4 weeks, (except tumor biopsy, puncture,)invasive dental procedures such as dental extraction, dental implants etc.

  4. Current or previous severe retinopathy who, in the judgment of the Investigator, are not suitable for enrollment

  5. A history of clinically significant cardiovascular or cerebrovascular disease, including, but not limiting to:

    • Severe arrhythmia or heart conduction disturbance, such as second-degree or third-degree atrio-ventricular block or ventricular arrhythmia indicated with medical intervention
    • QTc (by Fridericia): male >450 ms, female >470 ms
    • Major cardiovascular events within 6 months prior to first dose, including acute coronary syndrome, stroke, deep vein thrombosis, pulmonary-thromboembolism and other ≥Grade 3 arterial-thrombosis events, or congestive heart failure, or aortic dissection etc.;
    • New York Heart Association Class ≥ II;
    • Left ventricular ejection fraction(LVEF)<50%;
    • Uncontrolled hypertension (blood pressure≥140/90 mmHg even with antihypertensive therapy)
  6. Subjects with active leptomeningeal disease or brain metastases without being well controlled, except subjects with asymptomatic or treated brain metastases being stable imaging between 12 weeks before screening;

  7. Subjects with interstitial lung disease or radiation pneumonia in needs of corticosteroids therapy

  8. Subjects with clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention within 7 days prior to first dose;

  9. Subjects with malignant tumors in the last 5 years (not including non-melanoma skin cancer, breast cancer or cervical cancer in situ, and superficial bladder transient cell carcinoma that have been cured)

  10. A history of ≥ grade 3 bleeding episodes within 6 months prior to first dose; or currently ≥ grade 2 hemorrhage, with angioneoplasm/ vascular malformation, with high bleeding risks (such as active peptic ulcer or esophageal varices)

  11. Within 2 weeks prior to first dose of concomitant medication with strong inducers of CYP3A4, strong inhibitors of CYP3A4, or substrates with narrow therapeutic windows of CYP3A4;

  12. Subjects with ≥ Grade 2 (by CTCAE) toxicities caused by previous therapy (not including ≤Grade 2 peripheral neuropathy, alopecia, or other tolerated and no possible safety hazard events as determined by the investigator);

  13. Subjects with active hepatitis B, unless HBV-DNA titer in the normal range (for subjects with positive HBsAg but HBV-DNA titer eligible, prophylactic antiviral therapy except interferon is allowed); active hepatitis C (ANTI-HCV positive);

  14. Subjects with positive HIV antibodies or Treponema pallidum antibodies;

  15. Subjects with acute bacterial, viral or fungal infections, and in needs of systemic antimicrobial therapy;

  16. Pregnant or lactating females;

  17. Subjects with significant neuropsychiatric disorders, leading to poor compliance;

  18. Subjects with underlying diseases (including abnormal laboratory investigations), alcohol, drug abuse, or drug dependence, all which affect the interpretation of toxicities or adverse event, or decrease;

  19. Subjects with oral administration impossible, or in the conditions of malabsorption as determined by the investigator, such as dysphagia and intestinal obstruction, etc.;

  20. Subjects with significant liver cirrhosis, hepatatrophy, portal hypertension, or more than moderate volume of ascites;

  21. A history of organ transplant;

  22. A history of other severe systemic disease, or not suitable as determined by the investigator due to any other reasons;

  23. A history of inoculation with live vaccine within 28 days prior to first dose. Note: Seasonal influenza vaccine is a broadly inactivated vaccine and is permitted. Inactivated COVID-19 vaccines are permitted. COVID-19 mRNA vaccines are not allowed. Intranasal influenza vaccines are live vaccines and are not allowed.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ST-1898 Phase Ib

Dose Escalation: Subjects will be administered orally at 140mg, 160mg, 180mg, 220mg, QD during the study, until disease progression or intolerable toxicity.

Supplied as 5 mg and 40 mg tablets

실험적: ST-1898 Phase II

Dose Expansion: Subjects with unresectable or metastatic melanoma will be administered orally at recommended phase II dose from phase Ib once daily during the study, until disease progression or intolerable toxicity.

Supplied as 5 mg and 40 mg tablets

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase Ib Dose Escalation: The Number and frequency of treatment-related adverse events (AEs) and treatment related serious adverse events (SAEs)
기간: Approximately 18 months

AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0

Approximately 18 months
Phase Ib Dose Escalation: Recommended Phase 2 Dose (RP2D)
기간: Within the first cycle (21days)

RP2D was determined according to MTD. MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first cycle (21days) of treatment.

Within the first cycle (21days)
Phase II Expansion: Objective Response Rate (ORR)
기간: Approximately 18 months

ORR is defined as the percentage of participants who experience a CR or PR based on RECIST 1.1 (CR: Complete Response, Disappearance of all target lesions, PR: Partial Response, At least a 30% decrease in the sum of diameters of target lesions)

Approximately 18 months

2차 결과 측정

결과 측정
측정값 설명
기간
Phase Ib Dose Escalation: Trough concentration of ST-1898
기간: Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase Ib Dose Escalation (21 days per cycle), up to 10 weeks

To assess plasma pharmacokinetics (PK) of oral administration of ST-1898

Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase Ib Dose Escalation (21 days per cycle), up to 10 weeks
Phase Ib Dose Escalation: Peak concentration of ST-1898
기간: Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase Ib Dose Escalation (21 days per cycle), up to 10 weeks

To assess plasma pharmacokinetics (PK) of oral administration of ST-1898

Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase Ib Dose Escalation (21 days per cycle), up to 10 weeks
Phase Ib Dose Escalation: ORR
기간: Approximately 18 months

Objective Response Rate (ORR) per RECIST 1.1

Approximately 18 months
Phase Ib Dose Escalation: PFS
기간: Approximately 18 months

Progression-Free Survival (PFS) per RECIST 1.1

Approximately 18 months
Phase Ib Dose Escalation: DoR
기간: Approximately 18 months

DoR Duration of Response (DoR) per RECIST 1.1

Approximately 18 months
Phase Ib Dose Escalation: DCR
기간: Approximately 18 months

Disease Control Rate (DCR) per RECIST 1.1

Approximately 18 months
Phase Ib Dose Escalation: TTP
기간: Approximately 18 months

Time to Progression per RECIST 1.1

Approximately 18 months
Phase II Dose Expansion: The Number and frequency of treatment-related adverse events and serious adverse events (SAEs)
기간: Approximately 18 months

The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.

Approximately 18 months
Phase II Dose Expansion: Trough concentration of ST-1898
기간: Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase II Dose Expansion (21 days per cycle), up to 10 weeks

To assess plasma Trough concentration of oral administration of ST-1898 in subjects with unresectable or metastatic melanoma

Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase II Dose Expansion (21 days per cycle), up to 10 weeks
Phase II Dose Expansion: Peak concentration of ST-1898
기간: Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase II Dose Expansion (21 days per cycle), up to 10 weeks

To assess plasma Peak concentration of oral administration of ST-1898 in subjects with unresectable or metastatic melanoma

Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase II Dose Expansion (21 days per cycle), up to 10 weeks
Phase II Dose Expansion: PFS
기간: Approximately 18 months

Progression-Free Survival (PFS) per RECIST 1.1

Approximately 18 months
Phase II Dose Expansion: DoR
기간: Approximately 18 months

DoR Duration of Response (DoR) per RECIST 1.1

Approximately 18 months
Phase II Dose Expansion: DCR
기간: Approximately 18 months

Disease Control Rate (DCR) per RECIST 1.1

Approximately 18 months
Phase II Dose Expansion: TTP
기간: Approximately 18 months

Time to Progression per RECIST 1.1

Approximately 18 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Jun GUO, MD, Peking University Cancer Hospital & Institute

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 11월 7일

기본 완료 (추정된)

2026년 12월 1일

연구 완료 (추정된)

2026년 12월 1일

연구 등록 날짜

최초 제출

2024년 1월 3일

QC 기준을 충족하는 최초 제출

2024년 4월 6일

처음 게시됨 (실제)

2024년 4월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • ST-1898-203

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .